Login to Your Account



Threshold BPH Drug Hits Bump; Stock Tumbles On Liver Toxicity

By Randall Osborne


Monday, May 15, 2006
Threshold Pharmaceuticals Inc.'s stock took a walloping after news that the FDA had put the Phase II program with TH-070 (lonidamine) for benign prostatic hypoplasia on partial clinical hold because of liver enzyme abnormalities, and Threshold stopped dosing in the European Phase III trial, as well. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription